新藥技術(shù)轉(zhuǎn)讓背景和發(fā)展趨勢(編輯修改稿)
2024-11-14 15:54 本頁面
【文章內(nèi)容簡介】 ings – IPO, SPO (Common Shares) ? – Private Offerings – PIPE deals (Preferred Shares) ? 224。 In addition, partnering deals provides significant amounts of ? nondilutive financing to fund biotech panies 生物醫(yī)藥投資者看中什么 ? ? The Disappearance of Small Cap Biotech ($200M $1B) ? Over the past three years this category has shrank ? Companies that are short of cash and without news flow have been punished in the marketplace and moved into microcap territory ? Industry consolidation eliminated many panies ? Pharma and Biotech acquisitions at bargain prices ? Mergers of equals in the hopes of surviving the storm ? Institutional Investors are typically looking to invest $1050M ? They can’t do that with microcaps without affecting the stock price ? Investors want to see more small cap Biotechs ? Investors want to buy into Biotechs’ risk ? Ideally Phase II/III data outes within 612 months 收購與兼并 Mamp。A ? Pharma acquisitions of Biotech Companies (Pharma / Bio) ? Biotech mergers or acquisitions (Bio / Bio) ? Mamp。A deal activity has been elevated since 2021 ? BigCos search for products and platforms ? Biotech39。s investors seek liquidity ? Deal activity spiked in the summer of 2021 ? Significant gap exists on valuation of many panies ? Investors asking price ? Buyers perceived value ? Source: Deloitte Pharma / Biotech Biotech / Biotech 73 deals between 202108 ? 38 Public Companies (%) ? 35 Private Companies (%) ? 44 Product Companies (%) ? 29 Platform Companies (%) ? 29 Large Molecule Focus (%) ? 44 Small Molecule Focus (%) ? Average Valuation $1, ? Median Valuation $ ? Total Value $135, 90 deals between 202108 ? 33
教學(xué)課件相關(guān)推薦
鄂ICP備17016276號(hào)-1